Opening Disease Modifying Therapies in Spinal Muscular Atrophy
Disease Modifying Therapies in Spinal Muscular Atrophy
- Length
- 59 min
- Level
- Undergraduate
- Recorded
- University of Louisville2022
Chapter 1 of 7: Before the lecture
Rogers traces how one SMN2 nucleotide misdirects splicing, then weighs trial data for three SMA therapies.
Spinal muscular atrophy disease-modifying therapies transform outcomes for patients through gene replacement and RNA splicing correction. Amanda Rogers examines the molecular genetics of SMN1 and SMN2 genes, detailing how single nucleotide differences alter pre-mRNA splicing and protein production. Clinical trial data for nusinersen, onasemnogene abeparvovec, and risdiplam demonstrate significant improvements in event-free survival and motor milestone achievement. The lecture evaluates safety profiles, long-term outcomes, and the clinical impact of newborn screening programs. Financial considerations and ethical questions surrounding drug pricing conclude the discussion.
Spinal muscular atrophy disease-modifying therapies transform outcomes for patients through gene replacement and RNA splicing correction. Amanda Rogers examines the molecular genetics of SMN1 and SMN2 genes, detailing how single nucleotide differences alter pre-mRNA splicing and protein production. Clinical trial data for nusinersen, onasemnogene abeparvovec, and risdiplam demonstrate significant improvements in event-free survival and motor milestone achievement. The lecture evaluates safety profiles, long-term outcomes, and the clinical impact of newborn screening programs. Financial considerations and ethical questions surrounding drug pricing conclude the discussion.
Spinal muscular atrophy
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Nusinersen versus Sham Control in Later-Onset SMA
Nusinersen initiated in infants during the presymptomatic stage of SMA
Nusinersen in adults with 5q SMA: a non-interventional, multicenter, observational cohort study
Single-Dose Gene Replacement Therapy for SMA

This lecture
Talk 72 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in SMA
Risdiplam in Type 1 SMA